Latest & greatest articles for influenza

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on influenza or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on influenza and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for influenza

1. Influenza infection

Influenza infection Influenza infection - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Influenza infection Last reviewed: February 2019 Last updated: March 2019 Summary Characterised by upper and lower respiratory tract symptoms of rhinorrhoea, cough, fever, chills, headache, and myalgia. Typically presents in winter season. Can occur in local community outbreaks, epidemics, and, rarely, pandemics. Vaccination (...) for prevention is available. Definition Acute respiratory tract infection typically caused by seasonal influenza A or B virus. The virus is transmitted by inhalation of infected respiratory secretions that have been aerosolised through coughing, sneezing, or talking. Brankston G, Gitterman L, Hirji Z, et al. Transmission of influenza A in human beings. Lancet Infect Dis. 2007;7:257-265. http://www.ncbi.nlm.nih.gov/pubmed/17376383?tool=bestpractice.com History and exam winter season current influenza outbreak

2019 BMJ Best Practice

2. Corticosteroids as adjunctive therapy in the treatment of influenza. (PubMed)

Corticosteroids as adjunctive therapy in the treatment of influenza. Specific treatments for influenza are limited to neuraminidase inhibitors and adamantanes. Corticosteroids show evidence of benefit in sepsis and related conditions, most likely due to their anti-inflammatory and immunomodulatory properties. Although commonly prescribed for severe influenza, there is uncertainty over their potential benefits or harms. This is an update of a review first published in 2016.To systematically (...) assess the effectiveness and potential adverse effects of corticosteroids as adjunctive therapy in the treatment of influenza, taking into account differences in timing and doses of corticosteroids.We searched CENTRAL (2018, Issue 9), which includes the Cochrane Acute Respiratory infections Group's Specialised Register, MEDLINE (1946 to October week 1, 2018), Embase (1980 to 3 October 2018), CINAHL (1981 to 3 October 2018), LILACS (1982 to 3 October 2018), Web of Science (1985 to 3 October 2018

Full Text available with Trip Pro

2019 Cochrane

3. Adult Outpatients With Acute Cough Due to Suspected Pneumonia or Influenza: CHEST Guideline and Expert Panel Report

Adult Outpatients With Acute Cough Due to Suspected Pneumonia or Influenza: CHEST Guideline and Expert Panel Report Patients commonly present to primary care services with upper and lower respiratory tract infections, and guidelines to help physicians investigate and treat acute cough due to suspected pneumonia and influenza are needed.A systematic search was carried out with eight patient, intervention, comparison, outcome questions related to acute cough due to suspected pneumonia (...) or influenza.There was a lack of randomized controlled trials in the setting of outpatients presenting with acute cough due to suspected pneumonia or influenza who were not hospitalized. Both clinical suggestions and research recommendations were made on the evidence available and CHEST Expert Cough Panel advice.For outpatient adults with acute cough due to suspected pneumonia, we suggest the following clinical symptoms and signs are suggestive of pneumonia: cough; dyspnea; pleural pain; sweating, fevers

2019 EvidenceUpdates

4. Flucelvax Tetra - influenza vaccine

Flucelvax Tetra - influenza vaccine 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. EMA/753449/2018 EMEA/H/C/004814 Flucelvax Tetra (influenza vaccine [surface antigen inactivated prepared in cell cultures]) An overview (...) of Flucelvax Tetra and why it is authorised in the EU What is Flucelvax Tetra and what is it used for? Flucelvax Tetra is a vaccine used to protect adults and children from 9 years of age against influenza (flu). Influenza is mainly caused by two kinds of influenza virus, known as influenza A and B. Each of these circulate as different strains and subtypes, which change over time. Flucelvax Tetra contains proteins from four different inactivated influenza A and B virus strains (type A-H1N1, type A-H3N2

2019 European Medicines Agency - EPARs

5. Seasonal influenza vaccination of health care workers: evidence synthesis

Seasonal influenza vaccination of health care workers: evidence synthesis influenza vaccination 18 March 2019 Links Download reports (pdf) Seasonal influenza vaccination of health care workers: evidence synthesis What do we want to know? This review addresses the following questions: What are the views and experiences of healthcare workers (HCWs) regarding vaccination for seasonal influenza? What is known about the implementation and context of interventions to promote vaccination for seasonal (...) influenza among HCWs? Who wants to know and why? This systematic review provides policy-makers and people involved in delivering vaccination promotion interventions with an overview of what is known about HCWs’ perceptions and attitudes. The focus on qualitative evidence and contextual data from intervention studies can help us to understand what problems may be encountered in implementing interventions, and also to gain a broader and more critical understanding of the contexts of vaccination promotion

2019 EPPI Centre

6. 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza

2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza Influenza Search Search Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza Published : 19 December 2018 Timothy M. Uyeki, Henry H. Bernstein, John S. Bradley, Janet A. Englund, Thomas M. File Jr, Alicia M. Fry, Stefan Gravenstein, Frederick G (...) . Hayden, Scott A. Harper, Jon Mark Hirshon, Michael G. Ison, B. Lynn Johnston, Shandra L. Knight, Allison McGeer, Laura E. Riley, Cameron R. Wolfe, Paul E. Alexander, and Andrew T. Pavia For full document, including tables and references, please visit the . Abstract These clinical practice guidelines are an update of the guidelines published by the Infectious Diseases Society of America (IDSA) in 2009, prior to the 2009 H1N1 influenza pandemic. This document addresses new information regarding

2019 Infectious Diseases Society of America

7. The use and effectiveness of oseltamivir in influenza-related respiratory infections in people with chronic cardiac and pulmonary disease: a systematic review and meta-analysis of randomized controlled trials and observational studies

The use and effectiveness of oseltamivir in influenza-related respiratory infections in people with chronic cardiac and pulmonary disease: a systematic review and meta-analysis of randomized controlled trials and observational studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission

2019 PROSPERO

8. Systematic review and meta-analysis of the immunogenicity and reactogenicity of MF59-adjuvanted inactivated influenza vaccine among children aged <8 years

Systematic review and meta-analysis of the immunogenicity and reactogenicity of MF59-adjuvanted inactivated influenza vaccine among children aged <8 years Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

9. Alternative dose versus standard dose of trivalent influenza vaccine for immunocompromised patients: a meta-analysis of randomized control trials

Alternative dose versus standard dose of trivalent influenza vaccine for immunocompromised patients: a meta-analysis of randomized control trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

10. Influenza and vaccination: efficacy and safety in diabetes

Influenza and vaccination: efficacy and safety in diabetes Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2019 PROSPERO

11. Baloxavir marboxil (Xofluza) - For the treatment of acute uncomplicated influenza in patients who have been symptomatic for no more than 48 hours

Baloxavir marboxil (Xofluza) - For the treatment of acute uncomplicated influenza in patients who have been symptomatic for no more than 48 hours Drug Approval Package: Xofluza Film-Coated Tablets (Baloxavir marboxil) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Xofluza Film-Coated Tablets (Baloxavir marboxil) Company: Shionogi, Inc. Application Number: 210854 Approval Date: 10/24/2018 Persons with disabilities having problems accessing the PDF

2018 FDA - Drug Approval Package

12. Update: Can Newer Rapid Influenza Tests Rule Out Disease?

Update: Can Newer Rapid Influenza Tests Rule Out Disease? TAKE-HOME MESSAGE Although newer rapid in?uenza tests have improved our ability to rule out disease, they are still better at ruling in in?uenza. Change in management should be considered before testing. Update: Can Newer Rapid In?uenza Tests Rule Out Disease? EBEM Commentators Katie Pettit, MD Julie L. Welch, MD Department of Emergency Medicine Indiana University School of Medicine Indianapolis, IN Results Pooled diagnostic accuracy

2018 Annals of Emergency Medicine Systematic Review Snapshots

13. VAXIGRIPTETRA, tetravalent vaccine against seasonal influenza

VAXIGRIPTETRA, tetravalent vaccine against seasonal influenza Haute Autorité de Santé - VAXIGRIPTETRA, vaccin quadrivalent contre la grippe saisonnière Développer la qualité dans le champ sanitaire, social et médico-social Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les Médicaments VAXIGRIPTETRA, vaccin quadrivalent contre la grippe saisonnière Substance active (DCI) vaccin grippal quadrivalent, inactivé, à virion

2018 Haute Autorite de sante

14. INFLUVAC TETRA, tetravalent vaccine against seasonal influenza

INFLUVAC TETRA, tetravalent vaccine against seasonal influenza Haute Autorité de Santé - INFLUVAC TETRA, vaccin tétravalent contre la grippe saisonnière Développer la qualité dans le champ sanitaire, social et médico-social Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les Médicaments INFLUVAC TETRA, vaccin tétravalent contre la grippe saisonnière Substance active (DCI) vaccin grippal quadrivalent, inactivé, à antigènes de

2018 Haute Autorite de sante

15. The use of antiviral drugs for influenza: Guidance for practitioners

The use of antiviral drugs for influenza: Guidance for practitioners This practice point summarizes the use of antiviral drugs to manage influenza illness in children and youth. Recommendations are based on previously published Canadian recommendations for clinicians on the use of antiviral drugs to prevent and treat influenza. Detailed information on the selective use of chemoprophylaxis can be found in the original document, which also highlights the importance of secondary bacterial (...) infections (i.e., Streptococcus pneumoniae , methicillin-sensitive  Staphylococcus aureus and methicillin-resistant  S. aureus ) in cases of severe influenza illness. This document serves as a reference for all clinicians while providing general principles and a user-friendly flow diagram to assist decision-making. Keywords : Antiviral therapy; Children; Influenza; Neuraminidase inhibitors

2018 Canadian Paediatric Society

16. Vaccine recommendations for children and youth for the 2018/2019 influenza season

Vaccine recommendations for children and youth for the 2018/2019 influenza season The Canadian Paediatric Society continues to encourage annual influenza vaccination for ALL children and youth ≥6 months of age. Recommendations from the National Advisory Committee on Immunization (NACI) for the 2018/2019 influenza season are not substantially changed from those of last season. Quadrivalent vaccine, if available, is recommended for children 6 months to 17 years of age. Either inactivated (...) influenza vaccine or live attenuated influenza vaccine may be used for children and youth 2 to 17 years of age who are not immunocompromised. Keywords:   Children; Influenza vaccine; Inactivated influenza vaccine; LAIV; NACI

2018 Canadian Paediatric Society

17. VAXELIS, hexavalent vaccine against diphtheria, tetanus, poliomyelitis, pertussis, Haemophilus influenzae type b infections, hepatitis B

VAXELIS, hexavalent vaccine against diphtheria, tetanus, poliomyelitis, pertussis, Haemophilus influenzae type b infections, hepatitis B Haute Autorité de Santé - VAXELIS, vaccin hexavalent contre diphtérie, tétanos, poliomyélite, coqueluche, infections à Haemophilus influenzae type b, hépatite B Développer la qualité dans le champ sanitaire, social et médico-social Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les (...) Médicaments VAXELIS, vaccin hexavalent contre diphtérie, tétanos, poliomyélite, coqueluche, infections à Haemophilus influenzae type b, hépatite B Substance active (DCI) vaccin diphtérique, tétanique, coquelucheux (acellulaire, multicomposé), de l'hépatite B (ADNr), poliomyélitique (inactivé) et conjugué de l'Haemophilus de type b (adsorbé) INFECTIOLOGIE - Nouveau médicament Nature de la demande Inscription Avis de la CT du 11 octobre 2017 Pas d’avantage clinique démontré pour la primovaccination et le

2018 Haute Autorite de sante

18. Assessment and Treatment of Pregnant Women With Suspected or Confirmed Influenza

Assessment and Treatment of Pregnant Women With Suspected or Confirmed Influenza Assessment and Treatment of Pregnant Women With Suspected or Confirmed Influenza - ACOG Menu ▼ Assessment and Treatment of Pregnant Women With Suspected or Confirmed Influenza Page Navigation ▼ Number 753 Immunization, Infectious Disease, and Public Health Preparedness Expert Work Group The Society for Maternal-Fetal Medicine endorses this document. This Committee Opinion was developed by the American College (...) with other organizations, conflict of interest disclosures by representatives of the other organizations are addressed by those organizations. The American College of Obstetricians and Gynecologists has neither solicited nor accepted any commercial involvement in the development of the content of this published product. Assessment and Treatment of Pregnant Women With Suspected or Confirmed Influenza ABSTRACT: Pregnant and postpartum women are at high risk of serious complications of seasonal and pandemic

2018 American College of Obstetricians and Gynecologists

19. Avian influenza A (H5N1) virus infection

Avian influenza A (H5N1) virus infection Avian influenza A (H5N1) virus infection - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Avian influenza A (H5N1) virus infection Last reviewed: February 2019 Last updated: September 2018 Summary Notifiable condition. Infection control measures, such as standard, droplet, contact, and airborne precautions, are recommended. High case-fatality rate of approximately 53% among (...) . Definition A contagious disease of animals caused by viruses that infect birds and, less commonly, pigs. Avian influenza A viruses are highly species-specific but have infected other mammals and, on rare occasions, have crossed the species barrier to infect humans. Highly pathogenic avian influenza (HPAI) A H5N1 virus originating in poultry and wild birds can be transmitted to humans, with rare cases of infection transmitted between humans. Ungchusak K, Auewarakul P, Dowell SF, et al. Probable person

2018 BMJ Best Practice

20. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. (PubMed)

Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. Baloxavir marboxil is a selective inhibitor of influenza cap-dependent endonuclease. It has shown therapeutic activity in preclinical models of influenza A and B virus infections, including strains resistant to current antiviral agents.We conducted two randomized, double-blind, controlled trials involving otherwise healthy outpatients with acute uncomplicated influenza. After a dose-ranging (10 to 40 mg) placebo (...) -controlled trial, we undertook a placebo- and oseltamivir-controlled trial of single, weight-based doses of baloxavir (40 or 80 mg) in patients 12 to 64 years of age during the 2016-2017 season. The dose of oseltamivir was 75 mg twice daily for 5 days. The primary efficacy end point was the time to alleviation of influenza symptoms in the intention-to-treat infected population.In the phase 2 trial, the median time to alleviation of influenza symptoms was 23.4 to 28.2 hours shorter in the baloxavir groups

2018 NEJM